Legend Biotech Corp ADR (LEGN) concluded trading on Wednesday at a closing price of $30.36, with 4.24 million shares of worth about $128.82 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -27.83% during that period and on June 04, 2025 the price saw a gain of about 6.79%. Currently the company’s common shares owned by public are about 184.03M shares, out of which, 181.38M shares are available for trading.
Stock saw a price change of 7.32% in past 5 days and over the past one month there was a price change of -9.10%. Year-to-date (YTD), LEGN shares are showing a performance of -6.70% which decreased to -24.12% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $27.34 but also hit the highest price of $60.87 during that period. The average intraday trading volume for Legend Biotech Corp ADR shares is 1.50 million. The stock is currently trading 2.82% above its 20-day simple moving average (SMA20), while that difference is down -4.43% for SMA50 and it goes to -22.58% lower than SMA200.
Legend Biotech Corp ADR (NASDAQ: LEGN) currently have 184.03M outstanding shares and institutions hold larger chunk of about 46.77% of that.
The stock has a current market capitalization of $5.59B and its 3Y-monthly beta is at 0.13. It has posted earnings per share of -$1.19 in the same period. It has Quick Ratio of 5.07 while making debt-to-equity ratio of 0.36. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LEGN, volatility over the week remained 4.03% while standing at 3.88% over the month.
Stock’s fiscal year EPS is expected to rise by 12.62% while it is estimated to increase by 243.12% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Redburn Atlantic on October 08, 2024 offering a Buy rating for the stock and assigned a target price of $86 to it. Coverage by Truist stated Legend Biotech Corp ADR (LEGN) stock as a Buy in their note to investors on June 17, 2024, suggesting a price target of $88 for the stock. On May 24, 2024, H.C. Wainwright Reiterated their recommendations, while on May 23, 2024, Deutsche Bank Initiated their ratings for the stock with a price target of $60. Stock get a Sector outperform rating from Scotiabank on April 17, 2024.
